Montai Therapeutics

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Oak Hill Licenses Roche’s Rugonersen,

“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office

Pharma executives no longer ask whether AI is important in their industry – that much is certain, and it is already ubiquitous. As Lamine Mbow , global head of discovery research at Boehringer Ingelh